You just read:

Lilly Phase 3 REACH-2 Trial Data Published in The Lancet Oncology Shows Improvement in Overall Survival with CYRAMZA® (ramucirumab) in Second-Line AFP-High Hepatocellular Carcinoma Patients

News provided by

Eli Lilly and Company

Jan 18, 2019, 19:02 ET